<i>In vitro</i>and<i>in vivo</i>characterization of A‐796260: a selective cannabinoid CB₂receptor agonist exhibiting analgesic activity in rodent pain models

Abstract

These results further confirm the therapeutic potential of CB2 receptor-selective agonists for the treatment of pain. In addition, they demonstrate that A-796260 may be a useful new pharmacological compound for further studying CB2 receptor pharmacology and for evaluating its role in the modulation of pain.